Roivant Reports Chronic Period Data for RVT-3101 from the TU

This is the first-ever long-duration data reported for an anti-TL1A antibodyAt the expected Phase 3 once-monthly subcutaneous dose in the overall population, RVT-3101 treatment resulted in improved Clinical Remission1 (36% at week 56 vs. 29% at week 14) a...

Related Keywords

Switzerland , Boston , Massachusetts , United States , London , City Of , United Kingdom , Matt Gline , Stephanie Lee , Roivant Sciences Nasdaq , Roivant Sciences Forward , Roivant Sciences , Exchange Commission , Securities Exchange , Clinical Remission , Endoscopic Improvement , Endoscopic Remission , Securities Act , Securities Exchange Act , Risk Factors , Markets ,